#Switzerland #Claros Technologies #PFAS Treatment #Bachem AG #Bubendorf

Claros Technologies Expands Operations in Europe

Claros Technologies, recognized as a leader in technologies aimed at the permanent destruction of PFAS (per- and polyfluoroalkyl substances), has announced a significant advancement in its commercial operations. The company has successfully completed a pilot program utilizing its innovative ClarosTechUV™ system at Bachem AG's main facility in Bubendorf, Switzerland. This milestone not only reflects the efficacy of Claros' treatments but also signals a broader strategic move into the European market and the pharmaceutical manufacturing sector.

Achievements in PFAS Destruction

During an extensive two-week testing period, the ClarosTechUV™ system met and even surpassed the performance metrics set by Bachem, a prominent global producer of peptide and oligonucleotide active pharmaceutical ingredients (APIs). Known for its production of semaglutide, utilized in lucrative GLP-1 therapies for weight management and diabetes treatment, Bachem's commitment to sustainable manufacturing practices is evident.

The success of this pilot program showcases the versatility and practical application of Claros' technology, particularly under real-world manufacturing conditions. The ability to destroy trifuoroacetic acid (TFA), an ultra-short-chain PFAS, right at the source marks a revolutionary development in handling these complex substances. By integrating the ClarosTechUV™, Bachem is setting a precedent for responsible manufacturing in an industry that grapples with environmental concerns over hazardous materials.

Addressing Regulatory Challenges

The increasing scrutiny towards PFAS substances by regulatory bodies in both Europe and the United States highlights the urgent need for efficient treatment solutions. As authorities evaluate broader PFAS restrictions—like those potentially mandated under the European REACH framework—Bachem’s proactive engagement with Claros signifies a pivotal strategy in addressing environmental challenges associated with pharmaceutical production.

Michelle Bellanca, the CEO and Co-Founder of Claros, articulated the importance of their partnership with Bachem, stating, “This relationship represents a defining milestone for Claros and an important step forward for the global pharmaceutical industry.” The proactive deployment of the ClarosTechUV™ system shows how leading manufacturers are addressing the environmental implications of their operational practices while maintaining their production of vital therapeutic agents.

Environmental Commitment

Bachem's initiative reflects an integrated approach to environmental sustainability, as they seek to ensure that their processes align with global regulatory trends and public sentiments regarding environmental stewardship. After the treatment with the Claros system, Bachem reported that residual concentrations of TFA in their industrial wastewater were minimal, indicating remarkable effectiveness in reducing harmful emissions.

Discussing their commitment, André Casagrande, Site Manager at Bachem’s facility in Bubendorf, stated, “Innovation and environmental responsibility go hand in hand for us.” This bold affirmation signifies not only an operational shift in how pharmaceuticals can be manufactured but also reinforces the role businesses have in contributing to a more sustainable future.

The Future of Pharmaceutical Manufacturing

The ClarosTechUV™ system stands out not merely as a treatment technology but as a vital component of modern pharmaceutical manufacturing. Designed to integrate seamlessly into existing industrial wastewater systems, it offers a unique advantage by permanently neutralizing PFAS without the complications tied to traditional treatment methods. This innovative capability positions Claros at the forefront of environmental solutions within the industry.

The data gleaned from the Bachem pilot program will inform future commercial system designs, enhancing the efficacy and reliability of PFAS treatment technologies moving forward.

About Claros Technologies and Bachem AG

Founded in 2018 and headquartered in Minneapolis, Claros Technologies is dedicated to creating permanent destruction solutions for PFAS across various settings. The company aims to eliminate the environmental hazards associated with PFAS through its state-of-the-art technologies, which have demonstrated an ability to destroy up to 99.99% of target PFAS species.

Bachem AG, with over fifty years in the industry, specializes in the development and manufacture of peptide and oligonucleotide APIs, serving pharmaceutical and biotech companies worldwide. Their collaborative efforts with Claros reflect a sustained commitment to innovation and environmental protection in the pharmaceutical sector.

For more detailed information on their technologies and sustainability commitments, visit Claros Technologies and Bachem.